AXTI
AXT, Inc.
AXTI's fundamentals are strong, but it looks expensive: trading at 99x earnings, about four times its usual 23x. Analysts expect strong earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AXTI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AXTI's revenue, profitability, cash flow and balance sheet are all currently strong.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AXTI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $5.95 | -86% |
| Forward | 18x | $43.54 | — |
| Fair | 23x | $9.92 | -77% |
| Expensive | 96x | $42.09 | -3.3% |
| Current | 99x | $43.54 | — |
Historical ranges are pointers, not guarantees.
AXTI's PE is in its expensive range at 99x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its fair range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AXTI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
AXTI has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AXTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.40 | +445% |
| Q3 2026 | $0.44 | +$0.95 |
| Q2 2026 | $0.01 | +$0.55 |
| Q1 2026 | -$0.32 | +$0.10 |
| Q4 2025 | -$0.49 | -$0.22 |
| Q3 2025 | -$0.51 | -$0.26 |
| Q2 2025 | -$0.54 | -$0.22 |
| Q1 2025 | -$0.42 | -$0.02 |
| Q4 2024 | -$0.27 | +$0.16 |
AXTI has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AXTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $73.4M | +163% |
| Q2 2026 | $47.6M | +165% |
| Q1 2026 | $26.9M | +39% |
| Q4 2025 | $23M | -8.2% |
| Q3 2025 | $28M | +18% |
| Q2 2025 | $18M | -36% |
| Q1 2025 | $19.4M | -15% |
| Q4 2024 | $25.1M | +23% |
AXTI's revenue is growing: $73M last quarter, up 163% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 39% | +43 points |
| Q2 2026 | 22% | +59 points |
| Q1 2026 | -5.9% | +47 points |
| Q4 2025 | -17% | +7.9 points |
| Q3 2025 | -4% | +10 points |
| Q2 2025 | -38% | -31 points |
| Q1 2025 | -53% | -38 points |
| Q4 2024 | -25% | -7.1 points |
AXTI has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AXTI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AXTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $87.7M | +$99M |
| Q2 2026 | $3.6M | +$8.4M |
| Q1 2026 | -$13.1M | -$9.2M |
| Q4 2025 | $1.3M | +14% |
| Q3 2025 | -$11.3M | -$5M |
| Q2 2025 | -$4.9M | -949% |
| Q1 2025 | -$3.9M | +$9.3M |
| Q4 2024 | $1.1M | -48% |
AXTI's free cash flow has turned positive after six years mostly in the red: $79M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AXTI on cash flow, with more consistent year-over-year improvement.
AXTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +2.4M shares |
| 1 year | +51% | +22.2M shares |
| 3 years | +55% | +23.3M shares |
| 5 years | +54% | +23.1M shares |
| Available history | +67% | +26.4M shares |
AXTI has 66M diluted shares, up 51% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AXTI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AXTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -9.2x | Net Cash |
| Q2 2026 | -24.4x | Net Cash |
| Q2 2023 | 93.9x | High |
| Q1 2023 | 5.5x | High |
| Q4 2022 | 2.9x | Moderate |
| Q3 2022 | 2.2x | Moderate |
| Q2 2022 | -0.4x | Net Cash |
| Q1 2022 | -0.5x | Net Cash |
AXTI has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AXTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.5 | Neutral |
| Stochastic | 15.1 | Oversold |
AXTI's weekly RSI is 43 (neutral) and its Stochastic is 15 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AXTI PE vs Technology Sector
| Metric | AXTI | Sector median | Relative |
|---|---|---|---|
| PE | 99x | 28x | 255% above |
| PE % | 83 | 35 | 48 pts above |
AXTI is trading at 99x earnings, a 255% premium to the Technology sector's median of 28x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AXTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.3 | 27% below |
| 20 week MA | $61.9 | 30% below |
| 50 week MA | $58.0 | 25% below |
| 100 week MA | $30.5 | 43% above |
| 200 week MA | $16.8 | 159% above |
AXTI has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AXTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.04 | $9.64 | +139% |
| 2021 | $9.64 | $8.80 | -8.7% |
| 2022 | $8.80 | $4.40 | -50% |
| 2023 | $4.40 | $2.40 | -45% |
| 2024 | $2.40 | $2.28 | -5% |
| 2025 | $2.28 | $15.4 | +574% |
| 2026 YTD | $15.4 | $43.5 | +183% |
AXTI has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.